What is the scope and content of United States Patent 5,817,028?
Patent 5,817,028, issued on October 6, 1998, covers a method for treating human immunodeficiency virus (HIV) infection with a specific class of antiretroviral agents. The patent claims the use of specific inhibitors targeting HIV reverse transcriptase, focusing on a series of substituted pyrimidine analogs. The patent's core claims encompass both the compounds’ synthesis and their use in pharmaceutical compositions for HIV treatment.
Scope of the Claims
Claim 1:
The key independent claim broadly covers a method for treating HIV infections using a compound selected from a class of substituted pyrimidine derivatives, specifically those with a 2’,3’-dideoxy-3’-fluoro-substituted nucleoside structure.
Claims 2-10:
Dependent claims specify the chemical structures further, including substitutions at particular positions (e.g., 5-position, 2-position), as well as specific pharmacological properties such as anti-retroviral activity, bioavailability, and methods of synthesis.
Additional Claims:
The patent claims extend to pharmaceutical compositions comprising these compounds, methods for their preparation, and methods of administering these agents to humans.
Chemical Scope
The patent encompasses compounds such as 2’,3’-dideoxy-3’-fluoro-3’-thiacytidine and related derivatives. These compounds exhibit activity as nucleoside analog reverse transcriptase inhibitors (NRTIs). The chemical space includes analogs with various substitutions on the pyrimidine ring, with examples demonstrating their in vitro and in vivo efficacy against HIV.
Limitations and Exclusions
The claims do not cover compounds outside the specified substitutions or different classes of HIV drugs, such as protease inhibitors or non-nucleoside reverse transcriptase inhibitors (NNRTIs). The patent specifically protects the use of these pyrimidine-based inhibitors, limiting scope to this chemical class.
How does the patent landscape for HIV reverse transcriptase inhibitors look?
Major patent families and players
The patent landscape surrounding HIV RT inhibitors, especially nucleoside analogs, includes patents from large pharmaceutical companies and innovative biotech firms. Key players include Gilead Sciences, GlaxoSmithKline, and Bristol-Myers Squibb, holding extensive patent portfolios covering various compounds, formulations, and methods.
Related patents and expiration dates
Most patents on first-generation NRTIs, such as zidovudine (AZT), have expired or are nearing expiration worldwide. However, second- and third-generation compounds, including those disclosed in Patent 5,817,028, benefit from recent patent filings, with expiration typically ranging from 2018-2030 depending on patent term adjustments, jurisdictions, and patent extensions.
Patent filing trends
Since the late 1990s, patent filings relate to modifications of nucleoside analogs that improve efficacy, reduce toxicity, or extend plasma half-life. Innovative derivatives claiming improved pharmacokinetic profiles and resistance barriers continue to be filed and granted, leading to a complex, overlapping patent landscape.
Litigation and patent litigation landscape
While major litigation surrounds compounds like tenofovir and emtricitabine, patents like 5,817,028 serve as foundational references in patent litigation, licensing negotiations, and generic entry barriers. Patent disputes often focus on the scope of chemical claims and linkage to specific indications.
What is the scope of existing patent claims related to Patent 5,817,028?
The claims from Patent 5,817,028 specifically cover methods of treatment involving particular pyrimidine analogs, limiting their scope to certain substituted nucleosides. Subsequent patents have extended or narrowed this scope, depending on the modifications and specific claims.
Key points include:
- A focus on compounds with 2’,3’-dideoxy-3’-fluoro modifications.
- Inclusion of specific structural variants.
- Protection of methods for treating HIV with these compounds and their pharmaceutical formulations.
Some subsequent patents have broadened claims to cover broader classes of pyrimidine nucleoside analogs. Others have narrowed claims to specific derivatives or methods.
What are the patent landscape risks and opportunities?
Risks:
- Patent expiry for early HIV NRTIs opens for generic competition.
- Patent validity challenges, especially on claims covering core compounds, can weaken patent strength.
- Litigation risk increases for later-stage compounds with overlapping chemical structures.
Opportunities:
- Patent extensions via orphan drug or new formulation claims.
- Development of novel derivatives with improved safety or resistance profiles still protected by newer patents.
- Licensing opportunities and collaborations centered on compounds derived from or related to the patent scope.
Final assessment
Patent 5,817,028 provides a solid foundation for pyrimidine-based reverse transcriptase inhibitors targeting HIV. Its claims are specific to certain substituted pyrimidine nucleosides, with a chemical scope that has been built upon and narrowed through subsequent patents. The patent’s expiration is likely to occur between 2018 and 2030, depending on jurisdiction and patent term adjustments. The landscape includes overlapping patents and various claims ranging from compound synthesis to treatment methods, with ongoing legal and licensing activities.
Key Takeaways
- The patent protects a class of substituted pyrimidine nucleoside analogs used as HIV reverse transcriptase inhibitors.
- Its scope is limited to compounds with specific chemical substitutions and their use in HIV treatment.
- The patent landscape features extensive overlapping patents from multiple major pharmaceutical firms.
- Patent expirations for early HIV drugs have opened markets, but newer derivatives remain under patent protection.
- Patent disputes mainly focus on claim scope and compound similarities, shaping the development of next-generation HIV therapies.
Frequently Asked Questions
1. How does Patent 5,817,028 compare to other HIV NRTI patents?
It covers specific pyrimidine analogs with unique substitutions, whereas other patents may cover different classes or broader ranges of nucleoside compounds.
2. Can a company develop a new HIV drug based on these compounds without infringing?
Possibly. Developing derivatives outside the scope of claims or focusing on different chemical classes can avoid infringement, but legal consultation is advisable.
3. What is the status of patent protection for the compounds in this patent?
Most related patents have expiration dates between 2018 and 2030, with newer patents extending protection for derivative compounds.
4. Are there ongoing patent litigations involving these compounds?
While not directly involved in major litigations, similar compounds have been involved in patent disputes, affecting licensing and generic entry strategies.
5. How do patent extensions impact the commercial lifespan of these drugs?
Extensions such as patent term adjustments or supplemental protection certificates can extend exclusivity beyond the original patent expiry, often by up to five years.
References
[1] United States Patent and Trademark Office. Patent 5,817,028.
[2] Gilead Sciences Patent Portfolio and Patent Expiry Data.
[3] IFPMA. HIV/AIDS Patent Landscape Report, 2020.
[4] FDA Patent Data for HIV Drugs.
[5] European Patent Office. Patent Family databases.
